| __timestamp | Apellis Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 50829000 |
| Thursday, January 1, 2015 | 6356782 | 57305000 |
| Friday, January 1, 2016 | 4303743 | 116145000 |
| Sunday, January 1, 2017 | 10463151 | 159362000 |
| Monday, January 1, 2018 | 22639184 | 206366000 |
| Tuesday, January 1, 2019 | 67046483 | 228244000 |
| Wednesday, January 1, 2020 | 139401000 | 293355000 |
| Friday, January 1, 2021 | 176771000 | 401715000 |
| Saturday, January 1, 2022 | 277163000 | 459856000 |
| Sunday, January 1, 2023 | 500815000 | 542705000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational expenses is crucial for success. Over the past decade, Exelixis, Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Exelixis, Inc. consistently outpaced Apellis Pharmaceuticals in SG&A spending, peaking at approximately $543 million in 2023. This represents a nearly tenfold increase from their 2014 expenses. Meanwhile, Apellis Pharmaceuticals saw a staggering growth of over 17,000% in the same period, reaching around $501 million in 2023.
These trends highlight differing strategic priorities. Exelixis's steady increase suggests a focus on scaling operations, while Apellis's rapid rise may indicate aggressive market expansion. Understanding these dynamics offers valuable insights into the financial strategies of leading biotech firms.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE